Zura Bio Limited Class A Ordinary Shares

Zura Bio Limited is a clinical-stage biotechnology company that develops medicines for autoimmune and inflammatory disorders in the United States. Its pipeline includes Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody designed to bind and neutralize both IL-17A and BAFF in a single molecule, which is in Phase 2 clinical development. The company also develops Torudokimab (ZB-880), a fully human IgG4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 studies, and Crebankitug (ZB-168), a fully human IgG1 monoclonal antibody targeting interleukin-7 receptor alpha that has also completed Phase 1 studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.